411 related articles for article (PubMed ID: 8797592)
1. Dose-response relationship of dexrazoxane for prevention of doxorubicin-induced cardiotoxicity in mice, rats, and dogs.
Imondi AR; Della Torre P; Mazué G; Sullivan TM; Robbins TL; Hagerman LM; Podestà A; Pinciroli G
Cancer Res; 1996 Sep; 56(18):4200-4. PubMed ID: 8797592
[TBL] [Abstract][Full Text] [Related]
2. Protection against doxorubicin-induced cardiotoxicity in weanling rats by dexrazoxane.
Della Torre P; Mazué G; Podestà A; Moneta D; Sammartini U; Imondi AR
Cancer Chemother Pharmacol; 1999; 43(2):151-6. PubMed ID: 9923821
[TBL] [Abstract][Full Text] [Related]
3. Cardioprotection by dexrazoxane in rats treated with doxorubicin and paclitaxel.
Della Torre P; Imondi AR; Bernardi C; Podestà A; Moneta D; Riflettuto M; Mazué G
Cancer Chemother Pharmacol; 1999; 44(2):138-42. PubMed ID: 10412948
[TBL] [Abstract][Full Text] [Related]
4. Dexrazoxane protects against doxorubicin-induced cardiomyopathy: upregulation of Akt and Erk phosphorylation in a rat model.
Xiang P; Deng HY; Li K; Huang GY; Chen Y; Tu L; Ng PC; Pong NH; Zhao H; Zhang L; Sung RY
Cancer Chemother Pharmacol; 2009 Jan; 63(2):343-9. PubMed ID: 18379782
[TBL] [Abstract][Full Text] [Related]
5. Preclinical models of cardiac protection and testing for effects of dexrazoxane on doxorubicin antitumor effects.
Imondi AR
Semin Oncol; 1998 Aug; 25(4 Suppl 10):22-30. PubMed ID: 9768820
[TBL] [Abstract][Full Text] [Related]
6. Diminished molecular response to doxorubicin and loss of cardioprotective effect of dexrazoxane in Egr-1 deficient female mice.
Saadane N; Yue P; Alpert L; Mitmaker B; Kirby GM; Chalifour LE
Can J Physiol Pharmacol; 2001 Jun; 79(6):533-44. PubMed ID: 11430591
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of the topoisomerase II-inactive bisdioxopiperazine ICRF-161 as a protectant against doxorubicin-induced cardiomyopathy.
Martin E; Thougaard AV; Grauslund M; Jensen PB; Bjorkling F; Hasinoff BB; Tjørnelund J; Sehested M; Jensen LH
Toxicology; 2009 Jan; 255(1-2):72-9. PubMed ID: 19010377
[TBL] [Abstract][Full Text] [Related]
8. The influence of the time interval between monoHER and doxorubicin administration on the protection against doxorubicin-induced cardiotoxicity in mice.
Bruynzeel AM; Mul PP; Berkhof J; Bast A; Niessen HW; van der Vijgh WJ
Cancer Chemother Pharmacol; 2006 Nov; 58(5):699-702. PubMed ID: 16565833
[TBL] [Abstract][Full Text] [Related]
9. NTP Toxicology and Carcinogenesis Studies of Coumarin (CAS No. 91-64-5) in F344/N Rats and B6C3F1 Mice (Gavage Studies).
National Toxicology Program
Natl Toxicol Program Tech Rep Ser; 1993 Sep; 422():1-340. PubMed ID: 12616289
[TBL] [Abstract][Full Text] [Related]
10. Reduction of the cardiotoxicity of doxorubicin in rabbits and dogs by encapsulation in long-circulating, pegylated liposomes.
Working PK; Newman MS; Sullivan T; Yarrington J
J Pharmacol Exp Ther; 1999 May; 289(2):1128-33. PubMed ID: 10215696
[TBL] [Abstract][Full Text] [Related]
11. Protection against doxorubicin cardiomyopathy in rats: role of phosphodiesterase inhibitors type 4.
Mohamed HE; Asker ME; Ali SI; el-Fattah TM
J Pharm Pharmacol; 2004 Jun; 56(6):757-68. PubMed ID: 15231041
[TBL] [Abstract][Full Text] [Related]
12. Use of dexrazoxane and other strategies to prevent cardiomyopathy associated with doxorubicin-taxane combinations.
Sparano JA
Semin Oncol; 1998 Aug; 25(4 Suppl 10):66-71. PubMed ID: 9768827
[TBL] [Abstract][Full Text] [Related]
13. NTP Toxicology and Carcinogenesis Studies of o-Benzyl-p-Chlorophenol (CAS No. 120-32-1) in F344/N Rats and B6C3F1 Mice (Gavage Studies).
National Toxicology Program
Natl Toxicol Program Tech Rep Ser; 1994 Jan; 424():1-304. PubMed ID: 12616287
[TBL] [Abstract][Full Text] [Related]
14. Cardiotoxicity of doxorubicin/paclitaxel combination in rats: effect of sequence and timing of administration.
Saad SY; Najjar TA; Alashari M
J Biochem Mol Toxicol; 2004; 18(2):78-86. PubMed ID: 15122649
[TBL] [Abstract][Full Text] [Related]
15. NTP technical report on toxicity studies of urethane in drinking water and urethane in 5% ethanol administered to F344/N rats and B6C3F1 mice.
Chan PC
Toxic Rep Ser; 1996 Mar; (52):1-91, A1-9, B1-9 passim. PubMed ID: 11803705
[TBL] [Abstract][Full Text] [Related]
16. Role of (+-)-1,2-bis(3,5-dioxopiperazinyl-1-yl)propane (ICRF-187) in modulating free radical scavenging enzymes in doxorubicin-induced cardiomyopathy.
Alderton P; Gross J; Green MD
Cancer Res; 1990 Aug; 50(16):5136-42. PubMed ID: 2116226
[TBL] [Abstract][Full Text] [Related]
17. Dexrazoxane pre-treatment protects skinned rat cardiac trabeculae against delayed doxorubicin-induced impairment of crossbridge kinetics.
de Beer EL; Bottone AE; van Rijk MC; van der Velden J; Voest EE
Br J Pharmacol; 2002 Apr; 135(7):1707-14. PubMed ID: 11934811
[TBL] [Abstract][Full Text] [Related]
18. NTP Toxicology and Carcinogenesis Studies of Pentachloroanisole (CAS No. 1825-21-4) in F344 Rats and B6C3F1 Mice (Feed Studies).
National Toxicology Program
Natl Toxicol Program Tech Rep Ser; 1993 Apr; 414():1-284. PubMed ID: 12616284
[TBL] [Abstract][Full Text] [Related]
19. NTP Toxicology and Carcinogenesis Studies of 3,4-Dihydrocoumarin (CAS No. 119-84-6) in F344/N Rats and B6C3F1 Mice (Gavage Studies).
National Toxicology Program
Natl Toxicol Program Tech Rep Ser; 1993 Sep; 423():1-336. PubMed ID: 12616288
[TBL] [Abstract][Full Text] [Related]
20. NTP Toxicology and Carcinogenesis Studies of Theophylline (CAS No. 58-55-9) in F344/N Rats and B6C3F1 Mice (Feed and Gavage Studies).
National Toxicology Program
Natl Toxicol Program Tech Rep Ser; 1998 Aug; 473():1-326. PubMed ID: 12571677
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
